Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Clinical Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the First-line Treatment of IIIB/IIIC/IV Non-Small Cell Lung Cancer

Next Previous
Trial Profile

Phase I Clinical Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the First-line Treatment of IIIB/IIIC/IV Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cytokine-induced killer cell therapy (Primary) ; Gemcitabine (Primary) ; Pemetrexed (Primary) ; Sintilimab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CCICC-002 study

Most Recent Events

  • 06 Jun 2023 Results(n=33) assessing safety and efficacy of Autologous cytokine-induced killer (CIK) cell immunotherapy in combination with Sintilimab presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 08 Jun 2021 Status changed from recruiting to completed, according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
  • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top